Medlab Enters UK Through Distribution Agreement

Medlab Clinical has signed an exclusive distribution agreement with Cultech Ltd to expand into the UK.

Medlab Clinical Ltd (ASX: MDC) has signed and executed an exclusive distribution agreement with Cultech Ltd for the UK, allowing Medlab's nutraceutical products ORSBiotic™ and NanoCBD™ to be distributed by Cultech Ltd.

According to Medlab's website, ORSBiotic "contains selected probiotic species which can help maintain gastrointestinal homeostasis. Saccharomyces boulardii and zinc have clinical evidence for providing therapeutic support for various triggers of diarrhoea and may help reduce the occurrence of diarrhoea in children."

NanoCBD is a hemp-derived CBD formulation that contains 16.67 mg/mL cannabidiol (CBD) as an active ingredient, in a sub-micron spray applied to the oro-buccal membrane. The product is designed to help with anxiety and inflammation.

NanoCBD utilizes NanoCelle, the company's patented sub-micron delivery system. This takes the form of a mouth spray that is applied to the buccal membrane—also known as the inner cheek—which has proven to be a highly effective particle delivery method for cannabis-based medicines.

The UK expansion deal provides Medlab 20% royalties ex-factory under the transfer agreement, with both ORSBiotic and NanoCBD to be sold online within the next few months.

Medlab's expansion into the UK also comes just months after the company's October announcement that it would be launching the Medlab nutraceutical CBD range to the USA.

I have worked with [Cultech] for well over a decade and they are uniquely placed to expand trade into territories beyond the United Kingdom. Dr. Sean Hall, CEO of Medlab

Dr. Sean Hall, CEO of Medlab stated "our IP has commercial reality, and whilst we have medical and scientific validation, the real-world validation is the commercial opportunities. Medlab remains true to its IPO promise of finding good partners to provide longevity in commercial relationships."

To learn more about Medlab, visit their company HQ here.

Disclaimer: Past performance is not an indicator of future performance.

Get the Latest Marijuana News &
Content in your Inbox!

All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors

Louis O'Neill
Louis O'Neill

Louis is a writer based in Sydney with a focus on social and political issues. Having interviewed local politicians and entrepreneurs, Louis now focuses on cannabis culture, legislation & reform.

Leave a Reply

Your email address will not be published. Required fields are marked *